ABBOTT PARK, Ill. and UPPSALA, Sweden, July 14, 2009 (GLOBE NEWSWIRE) -- Abbott and Oasmia Pharmaceutical have announced a multi-year agreement to market one of the first cancer medications for dogs. The chemotherapeutic agent, called Paccal(r) Vet (micellar paclitaxel), represents the first generation of treatments of its kind and is currently being studied to treat Grade II and Grade III canine mast cell tumors where curative surgery cannot be performed.
